5 reasons to buy and hold this Australian stock forever

You might never want to see this stock if you buy it.

Key points
  • This Australian stock is a global leader in sleep and respiratory care, addressing critical health challenges with a robust competitive position and expanding market potential.
  • The company benefits from a resilient business model with recurring revenue from consumables and digital health, which enhances its financial stability.
  • ResMed offers significant growth opportunities with underdiagnosed markets and digital management expansion while maintaining an attractive valuation and strong management team.

Some companies come and go. Others build the kind of foundations that make them worth owning for a lifetime.

ResMed Inc. (ASX: RMD) is one of those rare names that sits comfortably in the second camp.

Over the past three decades, the sleep and respiratory care specialist has grown from a small Australian startup into a global medical technology leader helping millions of people breathe and sleep better.

While its share price has had its ups and downs, there are plenty of reasons long-term investors may want to hold ResMed forever. Here are five of them.

A businessman hugs his computer and smiles.

Image source: Getty Images

A global healthcare leader

ResMed's products are used by around 160 million people worldwide, and its technology addresses one of the biggest health challenges of the modern age, sleep apnoea. Untreated sleep disorders can lead to serious health issues such as cardiovascular disease and diabetes, making ResMed's mission both essential and profitable.

With strong global distribution, deep clinical expertise, and decades of research, the company has built a near-unassailable competitive position in sleep and respiratory care devices. And as awareness and diagnosis rates continue to rise, ResMed's total addressable market keeps expanding.

Recurring revenue

One of the most attractive features of this Australian stock's business is its recurring revenue stream. Once patients begin using its devices, they need ongoing mask and accessory replacements.

This generates a steady flow of consumable sales that now make up a good portion of ResMed's total revenue. It is a model that creates consistency and resilience, even when device sales fluctuate.

In addition, the company's digital health platform, which connects millions of devices to the cloud, adds another sticky revenue source. This combination of hardware, software, and data gives ResMed a structural advantage few competitors can replicate.

Long runway for global growth

ResMed's growth story is far from over. Sleep apnoea remains underdiagnosed in most markets, and emerging economies represent a massive untapped opportunity. In fact, the company estimates that there are over a billion sufferers of sleep apnoea, with most undiagnosed.

Beyond its core business, ResMed is also expanding into digital patient management, offering data-driven insights for clinicians and healthcare providers. This shift toward software and connected care gives the company a second engine of growth and one that can scale faster and at higher margins than its hardware business alone.

Attractive valuation

Despite rising by 10% this year, this Australian stock's valuation remains very attractive today.

For example, Citi, has a buy rating and a $51.00 price target on its shares, which implies around 25% upside from current levels.

But it isn't alone. Analysts at Macquarie, Canaccord Genuity, and Ord Minnett have the equivalent of buy ratings and price targets implying potential upside of 20%.

Proven management

A fifth reason to buy ResMed shares is its leadership team, led by CEO Mick Farrell.

It has demonstrated a consistent ability to grow profitably while reinvesting in innovation. The company has also shown discipline in capital allocation, funding R&D and acquisitions without compromising its balance sheet strength.

And with a solid pipeline of new products and a culture of steady execution, management continues to steer the company with a focus on sustainable growth.

Foolish takeaway

ResMed isn't a flashy stock. It doesn't chase hype or short-term fads. But it does something far more valuable. It solves a global health problem, generates recurring cash flow, and continues to innovate year after year.

With its attractive valuation, global leadership, and growing digital health presence, it could be an Australian stock to buy, hold, and quite possibly never sell.

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

A man and woman watch their device screens, making investing decisions at home.
Blue Chip Shares

If I could choose only one, would I buy Telstra or Wesfarmers shares?

I like both businesses, but if I could only add one to my portfolio today, there's a clear reason behind…

Read more »

A young woman drinking coffee in a cafe smiles as she checks her phone.
Blue Chip Shares

Why I'd buy Wesfarmers and Coles shares today

These businesses aren't trading at bargain prices, but I think their long-term opportunities justify a closer look.

Read more »

Happy young couple riding a motorbike together.
Blue Chip Shares

Why I'd buy these ASX blue-chip shares until at least 2036

I'm looking at three established businesses that could become more profitable over the next 10 years.

Read more »

Blue chips with stock written on them.
Blue Chip Shares

2 ASX blue-chip shares offering large dividend yields

I think these businesses have a very compelling future.

Read more »

Three smiling corporate people examine a model of a new building complex.
Blue Chip Shares

3 popular ASX shares I'd happily buy and hold until 2036

Wondering where to invest for the long term? I have my eyes on these shares.

Read more »

Person holding a blue chip.
Blue Chip Shares

2 top ASX blue-chip shares to buy according to experts

These two large businesses could be big opportunities.

Read more »

Happy young couple riding a motorbike together.
Blue Chip Shares

Why I think these 3 ASX shares could be turnaround winners in 2027

These shares have been having a tough time but could be worth a second look.

Read more »

Blue chips with stock written on them.
Blue Chip Shares

2 great ASX blue-chip shares I'd buy right now

I think these stocks can help build wealth.

Read more »